Translational Data at SITC 2021 from Adaptimmune’s Phase 1 SURPASS Trial Indicate Adding AKTi to Manufacturing May Contribute to Sustained Antitumor Activity of Next-gen SPEAR T-cells
12 November 2021 - 11:00PM
Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell
therapy to treat cancer, will present translational data from the
Phase 1 SURPASS trial during the poster session at the Society for
Immunotherapy of Cancer (SITC) annual meeting in Washington, D.C.
(or virtual) (Abstract #373) from November 12-14, 2021. In
addition, the Company will present a data update from four patients
treated in the radiation sub-study of the Phase 1 trial with
afami-cel (Abstract #376).
“The SURPASS data show that the addition of AKTi along with
next-gen enhancements results in an improved and more potent SPEAR
T-cell product,” said Karen Miller, Adaptimmune’s Senior Vice
President, Pipeline Research. “The data we continue to generate in
the Phase 1 SURPASS trial shows promising responses for patients
across multiple solid tumor indications. We will continue to
explore more next-gen enhancements and manufacturing improvements,
informed by our ongoing translational research, to deliver the best
cell therapies we can for people with cancer.”
Addition of AKTi during manufacturing results in
improved phenotype and proliferative potential of SPEAR T-cells –
attributes that may contribute to more sustained antitumor immune
responses
In vitro analyses of manufactured
product samples
- ADP-A2M4CD8 SPEAR T-cells were manufactured with and without
AKTi
- Samples manufactured with AKTi expanded more effectively during
manufacturing compared to samples without
- Flow cytometry analyses of ADP-A2M4CD8 SPEAR T-cells
demonstrated increased stem cell memory content of the transduced
population in samples manufactured in the presence of AKTi compared
to those manufactured without
- This increased stem cell memory content may be beneficial in
generating a more sustained immune response in patients
- Further experiments were conducted to evaluate the impact of
AKTi on SPEAR T-cell manufacturing: surplus pre-infusion apheresis
material from patients in the Phase 1 trial of afami-cel trial was
remanufactured into research-grade afami-cel with or without AKTi
- In vitro functional analyses showed that manufacturing
afami-cel SPEAR T-cells with AKTi can remodel gene expression in
favor of improved proliferation or cytotoxicity
Post-infusion analyses
- ADP-A2M4CD8 SPEAR T-cells manufactured with AKTi demonstrated
higher median persistence in peripheral blood of patients in the
Phase 1 SURPASS trial, by peak vector copy number and by peak
percent recovery, compared to those manufactured without
- Serum cytokine responses, measured in peripheral blood of
patients who received product manufactured with AKTi (n=14) showed
similar or greater induction of host immune response compared to
those who received product without AKTi (n=6)
Radiation sub-study (closed to enrollment in July 2021)
of the Phase 1 trial with afami-cel
- As of December 27, 2020 (data cut-off), 4 patients received
low-dose radiation and afami-cel
- Overall response rate was 33%, 1 partial response (PR)
(melanoma; reported in 2019) out of 3 evaluable patients
- Disease control rate was 100%, 1 PR, 2 stable diseases (SD) (1
patient with ovarian and 1 patient with head and neck cancer) out
of 3 evaluable patients
- Serum cytokine profiles were consistent with afami-cel
monotherapy, confirming no apparent impact of low-dose radiation on
persistence and peripheral immune response.
- There was greater detection of SPEAR T-cells in tumor biopsies
when infusion followed low-dose radiation, compared to samples from
patients who received afami-cel monotherapy in the Phase 1
trial
About Adaptimmune Adaptimmune is a
clinical-stage biopharmaceutical company focused on the development
of novel cancer immunotherapy products for people with cancer. The
Company’s unique SPEAR (Specific Peptide Enhanced Affinity
Receptor) T-cell platform enables the engineering of T-cells to
target and destroy cancer across multiple solid tumors.
Forward-Looking Statements This release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995 (PSLRA). These
forward-looking statements involve certain risks and uncertainties.
Such risks and uncertainties could cause our actual results to
differ materially from those indicated by such forward-looking
statements, and include, without limitation: the success, cost and
timing of our product development activities and clinical trials
and our ability to successfully advance our TCR therapeutic
candidates through the regulatory and commercialization processes.
For a further description of the risks and uncertainties that could
cause our actual results to differ materially from those expressed
in these forward-looking statements, as well as risks relating to
our business in general, we refer you to our Quarterly Report
on Form 10-Q filed with the Securities and Exchange Commission
(SEC) on November 4, 2021, and our other SEC
filings. The forward-looking statements contained in this
press release speak only as of the date the statements were made
and we do not undertake any obligation to update such
forward-looking statements to reflect subsequent events or
circumstances.
Adaptimmune Contacts: Media
Relations: Sébastien Desprez — VP, Corporate
Affairs and Communications T: +44 1235 430 583 M: +44
7718 453 176 Sebastien.Desprez@adaptimmune.com
Investor Relations: Juli P. Miller, Ph.D.
— VP, Investor Relations T: +1 215 825 9310 M: +1
215 460 8920 Juli.Miller@adaptimmune.com
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Apr 2023 to Apr 2024